New hope for lung cancer patients: experimental drug JYP0322 takes on chemo
NCT ID NCT07154368
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a new drug called JYP0322 against standard chemotherapy for people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) that has stopped responding to earlier targeted treatments. About 207 participants will be randomly assigned to receive either JYP0322 or chemotherapy. The main goal is to see if JYP0322 can delay cancer growth longer than chemotherapy. Patients who get chemotherapy may switch to JYP0322 if their cancer gets worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.